Krystal Biotech, Inc.
KRYS
$180.30
-$3.62-1.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 715.58% | 275.67% | 175.45% | 142.25% | 107.81% |
| Total Depreciation and Amortization | -33.19% | -18.81% | -9.56% | -2.51% | 18.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.92% | 163.56% | -276.51% | -290.36% | -302.90% |
| Change in Net Operating Assets | 62.47% | -169.34% | -1,807.94% | -163.95% | -1,470.40% |
| Cash from Operations | 238.98% | 160.97% | 83.65% | 57.96% | 11.70% |
| Capital Expenditure | 64.08% | 65.17% | 78.07% | 81.35% | 77.73% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2,761.78% | -3,164.04% | -803.53% | -191.80% | 90.90% |
| Cash from Investing | -297.78% | -202.55% | 253.65% | 197.22% | 172.44% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -84.08% | -84.02% | -77.88% | 470.02% | 465.34% |
| Repurchase of Common Stock | -619.09% | -619.09% | -619.09% | -619.09% | -15.41% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -86.68% | -86.61% | -80.60% | 467.03% | 473.60% |
| Foreign Exchange rate Adjustments | -193.59% | 92.98% | -302.90% | 187.01% | -280.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -106.85% | -99.61% | 22.32% | 269.78% | 209.52% |
